Muna Therapeutics ApS: Financial statements 2025
CVR: 41142871
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Muna Therapeutics ApS (CVR 41142871) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -60,636,000 and a net result of DKK -125,695,000 compared with DKK -173,625,357 the year before. Equity in the 2025 report amounted to DKK -120,338,000. The company had 18 employees in the financial year.
- Gross Profit
- DKK -60,636,000
- Profit/Loss
- DKK -125,695,000
- Equity
- DKK -120,338,000
- Total Assets
- DKK 311,124,000
- Employees
- 18
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -60.6 mio. | -125.7 mio. | -120.3 mio. | 18 |
| 2024 | - | -124.7 mio. | -173.6 mio. | 18.7 mio. | 18 |
| 2023 | - | -110.6 mio. | -140.3 mio. | 127 mio. | 18 |
| 2022 | - | -98.2 mio. | -127.7 mio. | 202 mio. | 16 |
| 2021 | - | -49.7 mio. | -61.5 mio. | 162.3 mio. | 7 |
Official annual report
How creditworthy is Muna Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of October 27, 2025, EY Godkendt Revisionspartnerselskab has been appointed auditor of Muna Therapeutics ApS.
As of October 27, 2025, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Muna Therapeutics ApS.
Muna Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -124,745,897, and the net result was DKK -173,625,357.
As of March 11, 2025, Luc Madeleine Albert Dochez has joined the board of directors of Muna Therapeutics ApS.
As of February 1, 2025, Reza Halse has left the board of directors of Muna Therapeutics ApS.
As of January 30, 2025, Camilla Petrycer Hansen has joined the board of directors of Muna Therapeutics ApS.
As of January 30, 2025, Morten Døssing has left the board of directors of Muna Therapeutics ApS.
About Muna Therapeutics ApS
Muna Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2020. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Michel Marcel A. Detheux. The board consists of Donald William Nicholson (chair), Camilla Petrycer Hansen, Cillian King and Eileen Elizabeth McGuire. The company's owners include Novo Holdings A/S, Sanofi Foreign Participations B.V. and Axxam S.p.A.. The company has 18 employees (2026). In 2025, the company reported a gross profit of DKK -60,636,000 and a net result of DKK -125,695,000 compared with DKK -173,625,357 the year before. Equity in the 2025 report amounted to DKK -120,338,000.